Tecvayli (teclistamab-cqyv) / Genmab, J&J 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   2 News 


«12345678910111213...1718»
  • ||||||||||  Review, Journal:  Therapeutic progress in relapsed/refractory multiple myeloma. (Pubmed Central) -  Apr 13, 2024   
    Additionally, novel antibody drugs, such as elotuzumab and selinexor, as well as bispecific antibodies, teclistamab and talquetamab, are currently undergoing clinical research with promising outcomes. However, chimeric antigen receptor-T cell therapy targeting B-cell maturation antigen remains the optimal approach for MM treatment.
  • ||||||||||  Darzalex (daratumumab) / J&J, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
    Review, Journal:  Targeting GPRC5D in multiple myeloma. (Pubmed Central) -  Apr 12, 2024   
    Additionally, ongoing trials examining talquetamab in combination with agents like daratumumab and teclistamab are discussed. We offer insights into the potential utilization of various GPRC5D based therapies in the treatment paradigm for MM, either independently or in combination with established therapies.
  • ||||||||||  Journal:  A pivotal decade for bispecific antibodies? (Pubmed Central) -  Mar 15, 2024   
    Notably, of the 13 currently approved bsAbs, two, emicizumab and faricimab, have achieved blockbuster status, showing the promise of this novel class of therapeutics. In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.
  • ||||||||||  Kineret (anakinra) / SOBI, Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Managing Neurotoxicity in B-cell Maturation Antigen (BCMA)-directed Therapy: A Case-series Study (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3506;    
    Despite employing a range of interventions, disease progression was observed, ultimately resulting in the death of both patients. It's vital to highlight that, in both of these patients, despite experiencing severe ICANS, imaging did not reveal any abnormalities.
  • ||||||||||  Darzalex (daratumumab) / J&J, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Clinically Significant Pulmonary Invasion in Multiple Myeloma - Associated Amyloid Light Chain Amyloidosis (San Diego Convention Center, Area I (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6398;    
    This refractory course prompted a planned inpatient trial of Teclistimab, which was complicated by cytokine release syndrome (CRS), cardiogenic shock, and ultimately death...This illustrates that clinically significant pulmonary disease in MM-associated amyloidosis may in fact be secondary to direct pulmonary vascular amyloid deposition and endothelial dysfunction, rather than restrictive cardiomyopathy from amyloid deposition. Additional studies and autopsies are needed to explore the effects of amyloid on pulmonary vasculature to further guide targeted therapy of pulmonary arterial hypertension in amyloidosis.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Trial primary completion date:  MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=140, Active, not recruiting, 
    Additional studies and autopsies are needed to explore the effects of amyloid on pulmonary vasculature to further guide targeted therapy of pulmonary arterial hypertension in amyloidosis. Trial primary completion date: Jun 2024 --> Oct 2024
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J, Talvey (talquetamab) / J&J
    SALVAGE SECOND AUTOLOGOUS STEM CELL TRANSPLANTS FOR PATIENTS WITH MYELOMA: A 24-YEAR RETROSPECTIVE AUDIT IN A NATIONAL TERTIARY REFERRAL CENTRE (1999-2022) (ePoster area) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2509;    
    The pattern of patient referrals has been relatively conservative with a median time between autologous transplants of 55 months overall and 85 months in the most recent cohort (2017-2022). It is likely that the selection of lower risk patients who were more likely to have a durable response to repeated treatment with high dose melphalan and the more recent availability of novel therapies such as anti-CD38 antibodies and bispecific antibodies such as Teclistamab and Talquetamab are factors in the superior OS in patients transplanted since 2015.
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J
    Review, Journal:  Teclistamab: Mechanism of action, clinical, and translational science. (Pubmed Central) -  Jan 28, 2024   
    Common adverse reactions included cytokine release syndrome, hematologic abnormalities, and infections. Teclistamab is currently being investigated as monotherapy as well as combination therapy across different MM indications.
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J
    EXTRAMEDULLARY PLASMACYTOMA WITH CARDIAC INVOLVEMENT (Moderated Poster Theater 12) -  Jan 26, 2024 - Abstract #ACC2024ACC_3223;    
    Clinical context, mass characteristics, and epidemiological factors drive decision making regarding the workup and treatment of cardiac masses. Employed as part of a multimodality imaging approach, CMRI can provide valuable noninvasive information to narrow the differential diagnosis.
  • ||||||||||  Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab) / Genmab, J&J, Talvey (talquetamab) / J&J
    Journal:  BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms. (Pubmed Central) -  Jan 9, 2024   
    Bispecific antibodies that engage T cells to target B cell maturation antigen (BCMA) or G protein-coupled receptor class C group 5 member D (GPRC5D) have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory MM leading to the recent accelerated approval of teclistamab, elranatamab and talquetamab by health agencies. Future challenges however remain to define their optimal dosing schedule and duration, sequencing and integration with established anti-MM therapeutics as well as delineating the biological and clinical mediators of immune escape.
  • ||||||||||  Clinical guideline, CAR T-Cell Therapy:  CAR T-Cell therapy for Myeloma: Where are we now and what is needed to move CAR T-cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (Pubmed Central) -  Jan 9, 2024   
    Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody...Sequencing CAR-T therapy with other options, including the 2 recently approved BCMA-directed T cell-engaging bispecific antibodies teclistamab and elranatamab, has become increasingly challenging owing to data showing inferior outcomes from CAR-T therapy after prior BCMA-directed therapy...To address the question of earlier use of CAR T Cells, several trials are either ongoing or planned, and results have recently been reported for 2 randomized trials of CAR T-cells showing improved progression free survival compared to standard of care therapy in 2 line (CARTITUDE-4) or 3 line therapy (KarMMA-3). With the anticipation of the FDA possibly expanding approval of CAR T cells to earlier lines of myeloma therapy, the American Society for Transplantation and Cellular Therapy (ASTCT) convened a group of experts to provide a comprehensive review of the studies that led to approval of CAR T-cells in late line therapy of myeloma, discuss the recently reported and ongoing studies designed to move CAR T-cell therapy to earlier lines of therapy, and to share insights and considerations for sequencing therapy and optimization of patient selection for BCMA directed therapies in current practice.
  • ||||||||||  Darzalex (daratumumab) / J&J, Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Enrollment open, Trial completion date, Trial primary completion date:  MASTER-2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (clinicaltrials.gov) -  Dec 19, 2023   
    P2,  N=300, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, Tecvayli (teclistamab) / Genmab, J&J, Talvey (talquetamab) / J&J
    A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_957;    
    Conclusion While this cohort was limited by patient size and short follow-up, ASCT prior to TCRT appears safe and can improve ALC, which could improve efficacy of TCRT. Studies with larger patient sizes will be necessary to further test this therapeutic approach.
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J
    Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma () -  Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_954;    
    Our data showed that additional advances in outpatient practice, including initial outpatient management of CRS and home visits are feasible, safe and reduce hospital resource utilization. Updated data on additional patients and new BsAb in practice will be presented.
  • ||||||||||  Review, Journal, Adverse events:  A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. (Pubmed Central) -  Nov 29, 2023   
    We searched the published literature using PubMed, plus congress abstracts, for the above list of drug names or classes and 'myeloma.' Optimal management of toxicities associated with these recently approved and emerging therapies will be critical in maximizing clinical benefit and aiding widespread adoption in routine clinical practice. We summarize current recommendations and guidelines and provide expert insights into supportive care requirements.